Centre médical Sheba
| Israël | Turquie | Espagne | |
| Immunothérapie avec Keytruda (Pembolizumab) | de $9,800 | de $3,300 | de $15,000 |
| Chimiothérapie pour le cancer du sein | de $22,500 | de $1,200 | de $3,500 |
| Chimiothérapie intrapéritonéale hyperthermique (HIPEC) | de $61,200 | de $22,500 | de $25,000 |
| Ablation de la vessie avec reconstruction | de $31,500 | de $15,000 | de $25,000 |
| Ablation de la vessie | de $28,500 | de $8,000 | de $25,000 |
Bookimed ne rajoute pas de frais pour les traitements de Cancer de la vessie. Les tarifs proviennent des listes de prix officielles des cliniques. Vous payez directement à la clinique pour votre traitement à votre arrivée dans le pays.
Bookimed s'engage pour votre sécurité. Nous ne travaillons qu'avec des établissements médicaux qui respectent des normes internationales élevées dans le traitement de Cancer de la vessie et qui possèdent les licences nécessaires pour accueillir des patients internationaux dans le monde entier.
Bookimed offre une assistance experte gratuite. Un coordinateur médical personnel vous accompagne avant, pendant et après votre traitement, en résolvant tous les problèmes. Vous n'êtes jamais seul dans votre parcours de traitement de Cancer de la vessie.
Dr. Shira Felder is a senior radiation oncologist. She focuses on gynecologic and urologic cancers. She has advanced expertise in VMAT, IMRT, SBRT, and gynecologic brachytherapy. She delivers precise treatment with fewer side effects.
She heads the Gynecologic Oncology Service at Sheba Medical Center. She is a senior physician in the Radiation Oncology Division. She earned her MD at Hadassah. She completed residency at Sheba and a fellowship in the Radiation Medicine Program at the University of Toronto and Princess Margaret Cancer Centre. She is board-certified in Radiation Oncology. She is a member of ESTRO, the Israeli oncology societies, the CPSO, and the CMA.
Her research covers brachytherapy patient safety. It also includes stereotactic ablative radiotherapy for stage I lung cancer. She has studied treatment delays in cervical cancer. She has examined vitamin D deficiency in oncology patients.
Dr. Yuri Goldes is a general surgeon with more than 20 years of clinical experience. He specializes in upper gastrointestinal and oncologic surgery. He is Deputy Director of the Department of General Surgery and Transplantation at Sheba Medical Center in Tel Aviv. He also leads the Upper GI Surgery Unit. He was named to Forbes Israel’s Best Doctors in 2025. He is ranked among Israel’s Best Gastrointestinal Surgeons by Forbes. In 2019, he received the Israeli Ministry of Health “Best Doctor of the Year” award.
He is an expert in advanced minimally invasive and robotic surgery. He treats diaphragmatic hernia, achalasia, GERD, and gallbladder disease. He also performs oncologic surgery for pancreatic, gastric, and esophageal cancers. He uses laparoscopic and robotic techniques.
He pioneered some of Israel’s first robotic oncologic resections of the stomach and pancreas. He is among a small group worldwide who perform minimally invasive Whipple procedures (pancreaticoduodenectomy) using advanced laparoscopy. He applies methods that improve outcomes and speed recovery. He provides personalized care.
Dr. Zohar Dotan is Head of the Urology Department at Sheba Medical Center. He is a leading uro-oncologist and a pioneer of robotic and laparoscopic urologic surgery in Israel.
He has authored more than 50 scientific publications. He is a regular speaker at international conferences. He has received awards from the American Association of Clinical Surgery, including recognition for research in prostate cancer treatment.
Leadership and credentials: Head of the Israeli Uro-Oncology Society. Assistant Professor at Tel Aviv University. Member of the Israeli, American, and European Urological Associations. Training: MD from Tel Aviv University and a PhD in Genetics. Urology residency at Sheba Medical Center. Fellowship in uro-oncology and laparoscopic surgery at Memorial Sloan Kettering, New York.
Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.
He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.